Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07507201CT.gov Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease | — | Recruiting | — | — | — |
NCT07305116CT.gov CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Systemic Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ucar T-Cell (this asset) | The Children's Hospital of Zhejiang University School of Medicine | P1 | CCC · 48 |
| Cyclophosphamide | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | BB |
| Iloprost | National Center for Research Resources (NCRR) | P3 | BB |
| Bosentan | Actelion | P3 | B |
| Rituximab | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2 | B |
| Nivestim | Fred Hutchinson Cancer Center | P2 | B |
| Recombinant Humanised Igg1 Kappa Anti-Oncostatin M Monoclonal Antibody Gsk2330811 | GlaxoSmithKline | P2 | B |
| Vipoglanstat | Gesynta Pharma AB | P2 | B |
+33 more in the Systemic Sclerosis cohort
Other indications for Ucar T-Cell
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| IgA Glomerulonephritis | — | P1 | CCC · 50 |
| Systemic Lupus Erythematosus | — | P1 | CCC · 50 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | — | P1 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ucar T-Cell in Systemic Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ucar-t-cell-systemic-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →